Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses
Authors
Keywords
-
Journal
PHARMACOGENOMICS JOURNAL
Volume 17, Issue 1, Pages 21-28
Publisher
Springer Nature
Online
2016-08-09
DOI
10.1038/tpj.2016.58
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses
- (2016) Jared M Campbell et al. PHARMACOGENOMICS
- Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
- (2014) Fei-fei Han et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer
- (2014) Goro Nakayama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
- (2014) Lei Cheng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Impact of granulocyte colony–stimulating factors in metastatic colorectal cancer patients
- (2014) A. Amadio et al. Current Oncology
- Effects of MTHFR Genetic Polymorphisms on Toxicity and Clinical Response of Irinotecan-Based Chemotherapy in Patients with Colorectal Cancer
- (2014) Ping Li et al. Genetic Testing and Molecular Biomarkers
- Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to theUGT1A1Genotype of Patients With Cancer
- (2014) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan Pharmacogenetics: A Finished Puzzle?
- (2014) Mitch A. Phelps et al. JOURNAL OF CLINICAL ONCOLOGY
- How do systematic reviews incorporate risk of bias assessments into the synthesis of evidence? A methodological study
- (2014) Srinivasa Vittal Katikireddi et al. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
- The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
- (2014) M M Dias et al. PHARMACOGENOMICS JOURNAL
- Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan
- (2013) Siew-Kee Low et al. CANCER SCIENCE
- Risk Factors for Severe Adverse Effects and Treatment-related Deaths in Japanese Patients Treated with Irinotecan-based Chemotherapy: A Postmarketing Survey†
- (2013) Tomoo Shiozawa et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal Cancer on Cost Effectiveness
- (2013) Martin Frank et al. PHARMACOECONOMICS
- Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
- (2013) X Liu et al. PHARMACOGENOMICS JOURNAL
- Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review
- (2013) J.C. Stingl et al. PHARMACOLOGY & THERAPEUTICS
- Polymorphisms of the UDP-Glucuronosyl Transferase 1A Genes Are Associated with Adverse Events in Cancer Patients Receiving Irinotecan-Based Chemotherapy
- (2013) Kazuyuki Inoue et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?
- (2013) Morgan Trammel et al. Current Oncology Reports
- Association between CYP2C8 (rs1934951) Polymorphism and Bisphosphonate-Related Osteonecrosis of the Jaws in Patients on Bisphosphonate Therapy: A Meta-Analysis
- (2012) Da-Ni Zhong et al. ACTA HAEMATOLOGICA
- The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
- (2012) M. J. Lamas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis
- (2012) Mafalda M Dias et al. PHARMACOGENOMICS
- Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity
- (2012) Gillian C. Barnett et al. RADIOTHERAPY AND ONCOLOGY
- UGT1A1predicts outcome in colorectal cancer treated with irinotecan and fluorouracil
- (2012) Yan Wang WORLD JOURNAL OF GASTROENTEROLOGY
- British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011
- (2011) S.J. Meggitt et al. BRITISH JOURNAL OF DERMATOLOGY
- Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms
- (2011) Taroh Satoh et al. CANCER SCIENCE
- Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review
- (2011) Ivan Diaz-Padilla et al. GYNECOLOGIC ONCOLOGY
- Pharmacogenetic and Germline Prognostic Markers of Lung Cancer
- (2011) Anne M. Horgan et al. Journal of Thoracic Oncology
- Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity
- (2011) Kalliopi P. Spyridopoulou et al. Pharmacogenetics and Genomics
- Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations
- (2011) H E Wheeler et al. PHARMACOGENOMICS JOURNAL
- Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
- (2010) Zhe-Yi Hu et al. EUROPEAN JOURNAL OF CANCER
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to K. Tay et al
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan pharmacogenomics
- (2010) Sharon Marsh et al. PHARMACOGENOMICS
- Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
- (2010) B Glimelius et al. PHARMACOGENOMICS JOURNAL
- Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer
- (2009) Heather Taffet Gold et al. CANCER
- Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives
- (2009) Mario Scartozzi et al. CANCER TREATMENT REVIEWS
- Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
- (2009) Glenn E Palomaki et al. GENETICS IN MEDICINE
- Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial
- (2009) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
- (2009) Alexander Stein et al. Therapeutic Advances in Medical Oncology
- Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
- (2008) E Rouits et al. BRITISH JOURNAL OF CANCER
- Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study
- (2008) Lesley Wood et al. BMJ-British Medical Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now